Tuhura Biosciences, Inc/nv 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
TuHURA Biosciences files an amendment to its 2025 Annual Report to include missing proxy information and correct management discussion disclosures.
NASDAQ
TuHURA Biosciences reported increased losses and substantial doubt about its ability to continue as a going concern despite advancing its immuno-oncology pipeline and securing recent financing.
NASDAQ
10-K: TuHURA Biosciences Reports 2024 10-K Filing, Outlines Clinical Development and Strategic Focus
TuHURA Biosciences details its 2024 financial results and provides an update on its clinical programs, including the planned Phase 3 trial for IFx-2.0 and the proposed merger with Kineta, Inc.
NASDAQ
Kintara Therapeutics shifts its focus to REM-001 after VAL-083 fails to outperform standard care in glioblastoma, and stockholders approve a merger with TuHURA Biosciences.